Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
An adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose. She had been commenced on the ultra-long-acting insulin, degludec, with the aim of reducing ketoacidosis episodes in response to inte...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2018-06-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Online Access: | https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-18-0044 |
id |
doaj-d19fccaf6a7b4144ad164c59a4816e17 |
---|---|
record_format |
Article |
spelling |
doaj-d19fccaf6a7b4144ad164c59a4816e172020-11-24T23:10:04ZengBioscientificaEndocrinology, Diabetes & Metabolism Case Reports2052-05732052-05732018-06-01111410.1530/EDM-18-0044Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring systemHarmony Thompson0Helen Lunt1Cate Fleckney2Steven Soule3Department of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New ZealandDepartment of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New Zealand; Department of Medicine, University of Otago Christchurch, Christchurch, New ZealandDepartment of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New ZealandDepartment of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New Zealand; Department of Medicine, University of Otago Christchurch, Christchurch, New ZealandAn adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose. She had been commenced on the ultra-long-acting insulin, degludec, with the aim of reducing ketoacidosis episodes in response to intermittent refusal to take insulin. Insulin degludec was administered under supervision as an outpatient. Because it was anticipated that she would attempt a degludec overdose at some stage, the attending clinicians implemented a proactive management plan for this (and related) scenarios. This included long-term monitoring of interstitial glucose using the Abbott Freestyle Libre flash glucose monitor. The patient took a witnessed overdose of 242 units of degludec (usual daily dose, 32 units). She was hospitalised an hour later. Inpatient treatment was guided primarily by interstitial glucose results, with capillary and venous glucose tests used as secondary measures to assess the accuracy of interstitial glucose values. Four days of inpatient treatment was required. The patient was managed with high glycaemic loads of food and also intermittent intravenous dextrose. No hypoglycaemia was documented during the admission. In summary, while a degludec overdose may require several days of inpatient management, in situations where proactive management is an option and the dose administered is relatively modest, it may be possible to avoid significant hypoglycaemia. In addition, this case demonstrates that inpatient interstitial glucose monitoring may have a role in managing insulin overdose, especially in situations where the effect of the insulin overdose on glucose levels is likely to be prolonged.https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-18-0044 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Harmony Thompson Helen Lunt Cate Fleckney Steven Soule |
spellingShingle |
Harmony Thompson Helen Lunt Cate Fleckney Steven Soule Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system Endocrinology, Diabetes & Metabolism Case Reports |
author_facet |
Harmony Thompson Helen Lunt Cate Fleckney Steven Soule |
author_sort |
Harmony Thompson |
title |
Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system |
title_short |
Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system |
title_full |
Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system |
title_fullStr |
Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system |
title_full_unstemmed |
Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system |
title_sort |
insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the freestyle libre flash glucose monitoring system |
publisher |
Bioscientifica |
series |
Endocrinology, Diabetes & Metabolism Case Reports |
issn |
2052-0573 2052-0573 |
publishDate |
2018-06-01 |
description |
An adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose. She had been commenced on the ultra-long-acting insulin, degludec, with the aim of reducing ketoacidosis episodes in response to intermittent refusal to take insulin. Insulin degludec was administered under supervision as an outpatient. Because it was anticipated that she would attempt a degludec overdose at some stage, the attending clinicians implemented a proactive management plan for this (and related) scenarios. This included long-term monitoring of interstitial glucose using the Abbott Freestyle Libre flash glucose monitor. The patient took a witnessed overdose of 242 units of degludec (usual daily dose, 32 units). She was hospitalised an hour later. Inpatient treatment was guided primarily by interstitial glucose results, with capillary and venous glucose tests used as secondary measures to assess the accuracy of interstitial glucose values. Four days of inpatient treatment was required. The patient was managed with high glycaemic loads of food and also intermittent intravenous dextrose. No hypoglycaemia was documented during the admission. In summary, while a degludec overdose may require several days of inpatient management, in situations where proactive management is an option and the dose administered is relatively modest, it may be possible to avoid significant hypoglycaemia. In addition, this case demonstrates that inpatient interstitial glucose monitoring may have a role in managing insulin overdose, especially in situations where the effect of the insulin overdose on glucose levels is likely to be prolonged. |
url |
https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-18-0044 |
work_keys_str_mv |
AT harmonythompson insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem AT helenlunt insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem AT catefleckney insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem AT stevensoule insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem |
_version_ |
1725608200473935872 |